Company Profile

CANBRIDGE-B

1228 Biotechnology
Description

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Livmarli, an oral, minimally-absorbed, reversible IBAT inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also engages in the development of CAN008, a CD95-Fc fusion protein that is in Phase 2/3 clinical trial for the treatment of glioblastoma multiforme; CAN106, an anti-C5 mAb that has completed Phase I clinical trial for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human enzyme replacement therapy (ERT) that is in Phase 2/3 clinical trials for gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; CAN202, a gene therapy program utilizing AAV sL65 capsid for pompe disease; and CAN 203, a gene therapy program that utilizes AAV SMN1 for the treatment of spinal muscular atrophy. It has a license agreement with Mirum for the development, commercialization, and manufacturing, under certain conditions, of Livmarli. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.

Reports

This company has 4 ESG reports available.

ESG Performance Overview

Select a KPI indicator to view performance trend

KPI Indicators

A1.2 Direct (Scope 1) and Indirect (Scope 2) GHG Emissions
56 Data Points
Indicator Data Points Actions
Total GHG Emissions Intensity (By Employee) 7
Scope 1 GHG Emissions Intensity (By Employee) 7
Scope 2 GHG Emissions Intensity (By Employee) 7
Scope 3 GHG Emissions Intensity (By Employee) 7
Total GHG Emissions 7
Direct GHG Emissions (Scope 1) 7
Indirect Energy Emissions (Scope 2) 7
Total Other Indirect Energy Emissions (Scope 3) 7
A1.3 Hazardous Waste
3 Data Points
Indicator Data Points Actions
Total Hazardous Waste Intensity (By Employee) 3
A1.4 Non-Hazardous Waste
15 Data Points
Indicator Data Points Actions
Non-Hazardous Waste Recycled 6
Non-Hazardous Waste Disposed 6
Paper Waste 1
Total Non-Hazardous Waste Intensity (By Employee) 2
A1.5 Emission Targets
1 Data Points
Indicator Data Points Actions
GHG Emissions Reduction Percentage Compared to Last Year 1
A1.6 Hazardous and Non-Hazardous Waste Targets
1 Data Points
Indicator Data Points Actions
Non-Hazardous Waste Intensity Reduction Percentage Compared to Last Year 1

A2.1 Energy Consumption
60 Data Points
Indicator Data Points Actions
Purchased Electricity Intensity (By Employee) 5
Energy Consumption Intensity (By Employee) 3
Direct Energy Intensity (By Employee) 9
Indirect Energy Intensity (By Employee) 3
Total Electricity Consumption Intensity (By Employee) 3
Total Energy Consumption 3
Total Direct Energy Consumption 6
Total Non-Renewable Fuel Consumption 3
Gasoline Consumption 6
Fossil Fuel Consumption 2
Total Indirect Energy Consumption 6
Total Purchased Energy 2
Purchased Electricity 6
Grid Electricity Consumption 3
A2.2 Water Consumption
7 Data Points
Indicator Data Points Actions
Water Consumption 1
Water Consumption in Office 5
Water Consumption Intensity (By Revenue) 1

B1.1 Amount and Distribution of Workforce
29 Data Points
Indicator Data Points Actions
Number of Total Employees 2
Number of Male Employees 1
Number of Female Employees 1
Percentage of Male Employees 2
Percentage of Female Employees 2
Number of Full-time Employees 1
Percentage of Full-time Employees 2
Number of Employees Aged Below 30 1
Number of Employees Aged 30-50 1
Number of Employees Aged Above 50 1
Percentage of Employees Aged Below 30 2
Percentage of Employees Aged 30-50 2
Percentage of Employees Aged Above 50 2
Number of Employees in Hong Kong 1
Number of Employees in Mainland China 1
Number of Employees in United States 1
Percentage of Employees in Hong Kong 2
Percentage of Employees in Mainland China 2
Percentage of Employees in United States 2
B1.2 Employee Turnover Rate
36 Data Points
Indicator Data Points Actions
Turnover Rate of Female Employees 4
Turnover Rate of Male Employees 4
Turnover Rate of Employees Aged Below 30 4
Turnover Rate of Employees Aged 30-50 4
Turnover Rate of Employees Aged Above 50 4
Turnover Rate of Employees in Hong Kong 4
Turnover Rate of Employees in Mainland China 4
Turnover Rate of Total Employees 4
Turnover Rate of Employees in United States 4

B3.1 The Percentage of Employees Trained
42 Data Points
Indicator Data Points Actions
Percentage of Employees Trained 7
Percentage of Trained Male Employees 7
Percentage of Trained Female Employees 7
Percentage of Trained Senior Management 7
Percentage of Trained Middle Management 7
Percentage of Trained General Employees 7
B3.2 Average Training Hours Completed per Employee
42 Data Points
Indicator Data Points Actions
Average Training Hours per Employee 7
Average Training Hours (Male) 7
Average Training Hours (Female) 7
Average Training Hours (Senior Management) 7
Average Training Hours (Middle Management) 7
Average Training Hours (General Staff) 7

B8.2 Resources Contributed to the Community
5 Data Points
Indicator Data Points Actions
Total Social Investment 2
Total Public Welfare Donations 1
Total Volunteer Service Hours 2

General
4 Data Points
Indicator Data Points Actions
Turnover Rate of Employees in Taiwan 4

ESG Reports